Clinical trial
A Phase II Open Label Study of Brentuximab Vedotin in Combination With CHEP in Patients With Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL)
NCT05006664 is registered in ClinicalTrials.gov with Czech Lymphoma Study Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Open Label Study of Brentuximab Vedotin in Combination With CHEP in Patients With Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL)
- Lead sponsor
- Czech Lymphoma Study Group
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- October 31, 2021
- Completion date
- October 31, 2024
- Enrollment
- 33 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.